PRESENTED AT EACR 2024

Reconstructing tumor microenvironment with patient-derived organoids for derisking Immuno-Oncology therapies

Recent advances in cancer immunotherapy have positively impacted the life expectancy of patients for an extensive range of clinical indications. With new treatment strategies and druggable targets being identified, the number of patients eligible for cancer immunotherapy is expected to expand steadily. However, promising therapeutic developments face hurdles in translating preclinical findings into therapy since conventional 2D cancer models hold low clinical predictive value. We developed different assays in which different PDOS from colorectal (CRC) and non-small cell lung cancer (NSCLC) tumors were co-cultured with different cell types (T cells, PBMCs, macrophages) and screening readouts such as imaging-based cell viability, flow cytometry, and cytokine secretion. These tools are designed to expedite IO drug development, providing a reliable and efficient platform for preclinical research.

Download this poster to discover:

• The establishment of co-cultures with organoids and components of the tumor microenvironment (TME)
• Data demonstrating the application of the platform for investigating myeloid cells-targeting immunotherapy
• Data highlighting the application of the platform for assessing toxicity and efficacy of bispecific antibodies